[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,69,94,128,162,192,217,249,274,297,317],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644253","comparison-of-m-tapa-and-espb-for-postoperative-pulmonary-function-after-laparoscopic-cholecystectomy-100644253",false,"NCT07666646","Comparison of M-TAPA and ESPB for Postoperative Pulmonary Function After Laparoscopic Cholecystectomy","Comparison of the Effects of Erector Spinae Plane Block and Modified Thoracoabdominal Nerve Block Through Perichondrial Approach on Postoperative Pulmonary Function and Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Patients aged 18-70 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Patients scheduled for elective laparoscopic cholecystectomy\n* Patients who provide written informed consent\n* Patients who are able to cooperate and perform pulmonary function tests (PFTs)\n\nExclusion Criteria:\n\n* Coagulation disorders or anticoagulant therapy contraindicating regional anesthesia\n* Infection at the planned block site\n* Known allergy to local anesthetic agents\n* Conversion to open surgery\n* Hemodynamic instability\n* Inability to cooperate with pulmonary function tests (PFTs)\n* Pre-existing severe pulmonary disease (e.g., severe chronic obstructive pulmonary disease or restrictive lung disease)\n* Chronic opioid use or opioid dependence\n* Pregnancy or breastfeeding\n* Active smokers\n* Body mass index (BMI) \\> 35 kg\u002Fm²","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, randomized, controlled clinical trial aims to compare the effects of two ultrasound-guided fascial plane blocks, the Erector Spinae Plane Block (ESPB) and the Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA), on postoperative pulmonary function and analgesic consumption in patients undergoing laparoscopic cholecystectomy. Laparoscopic cholecystectomy is one of the most frequently performed abdominal surgical procedures worldwide. Despite minimally invasive techniques, postoperative pain remains a significant clinical problem due to port-site trauma, pneumoperitoneum, diaphragmatic irritation, and visceral manipulation.\n\nInadequate pain control may lead to impaired respiratory mechanics, reduced mobilization, delayed recovery, and an increased risk of postoperative pulmonary complications. Postoperative pulmonary dysfunction is a common consequence of upper abdominal surgery and may persist for several days, contributing to reductions in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), which are associated with increased postoperative morbidity.\n\nAlthough opioid-based analgesia is widely used, it is associated with adverse effects such as respiratory depression, nausea, vomiting, ileus, and delayed recovery. Therefore, regional anesthesia techniques and multimodal analgesia strategies are increasingly recommended to reduce opioid consumption while improving pain control.\n\nESPB and M-TAPA are ultrasound-guided fascial plane blocks used for postoperative analgesia in abdominal surgery. ESPB provides somatic and visceral analgesia through the spread of local anesthetic affecting the spinal nerve rami, while M-TAPA targets the anterior branches of the thoracoabdominal nerves to provide extensive anterior and lateral abdominal wall analgesia.\n\nDespite their increasing use, there is limited high-quality comparative evidence evaluating the effects of ESPB and M-TAPA on postoperative pulmonary function and opioid consumption in laparoscopic cholecystectomy. This study compares these two regional anesthesia techniques in a randomized controlled design to evaluate their impact on postoperative respiratory function and analgesic requirements.",[27,28],"Pulmonary Function","Post Operative Pain Control","NOT_YET_RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-24","ACTUAL",{"date":35,"type":21},"2026-07-01",{"date":37,"type":21},"2027-03-01",{"name":39,"class":40},"Kayseri City Hospital","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":41},"100590009","the-effect-of-inspiratory-muscle-training-with-substance-use-disorder-100590009","NCT06961838","The Effect of Inspiratory Muscle Training With Substance Use Disorder","Inclusion Criteria:\n\n* Being older than 18 years\n\n  * Meeting the current Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for Substance Use Disorder\n  * Receiving inpatient treatment\n  * Substance use for more than one year\n  * Being able to follow simple instructions\n  * Not having any visual and auditory pathology\n  * Being able to cooperate with the devices used.\n\nExclusion Criteria:\n\n* Failure to comply with the treatment and assessment program\n* Participation in a structured physiotherapy\u002Fexercise program in the last 6 months\n* Presence of current psychotic symptoms\n* Presence of any physical disability or medical problem\n* Presence of respiratory system problems such as asthma and tuberculosis and infectious health problems (e.g. HIV, hepatitis B).",{"count":49,"type":21},34,[24],"The aim was to investigate the effectiveness of inspiratory muscle training on dyspnoea, pulmonary function, respiratory muscle strength, cough capacity, functional exercise capacity, substance craving, depression, anxiety and quality of life in individuals with substance use disorder.",[53,54,27,55],"Substance Abuse Disorder","Exercise","Rehabilitation",[57,54,55,27,58],"Substance Use Disorder","Muscle Training","RECRUITING","2026-04-28",{"date":62,"type":33},"2026-05-05",{"date":64,"type":33},"2025-07-03",{"date":35,"type":21},{"name":67,"class":68},"Uskudar University","OTHER",{"id":70,"slug":4,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100625339","NCT07421349","Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy Peers","Inclusion Criteria For Children With Hearing Loss Group:\n\n* Aged between 7 and 16 years\n* Diagnosed with hearing loss\n* No neurological or orthopedic disorders\n* No syndrome and\u002For disease causing intellectual disability, developmental disorder, or visual impairment\n* No use of medication affecting respiratory function within the last 3 months\n* Written informed consent obtained from parent or legal guardian\n\nFor Healthy Control Group:\n\n* Aged between 7 and 16 years\n* No hearing impairment\n* No neurological or orthopedic disorders\n* No syndrome and\u002For disease causing intellectual disability, developmental disorder, or visual impairment\n* No use of medication affecting respiratory function within the last 3 months\n* Written informed consent obtained from parent or legal guardian\n\nExclusion Criteria (Both Groups)\n\n* Intellectual disability preventing participation in assessment procedures\n* Presence of chronic respiratory disease\n* Inability to perform pulmonary function or respiratory muscle strength tests properly",true,"7 Years","16 Years",{"count":78,"type":21},30,"OBSERVATIONAL","This study aims to compare pulmonary function and respiratory muscle strength between children with hearing impairment and their healthy peers. Hearing plays a critical role not only in communication but also in cognitive, sensory, and psychomotor development. Children with hearing impairment may experience balance and coordination problems, vestibular dysfunction, and reduced muscle strength, which may negatively affect respiratory function.\n\nAlthough several studies have evaluated pulmonary function in children with hearing impairment, research investigating respiratory muscle strength in this population is limited. To our knowledge, no peer-reviewed study has directly compared respiratory muscle strength between children with hearing impairment and healthy controls.\n\nThis study will compare spirometric parameters and respiratory muscle strength measurements between children with hearing impairment and age-matched healthy controls.",[82,27,83,84],"Hearing Loss, Bilateral Sensorineural","Respiratory Muscle Strength","Children","2026-02-12",{"date":87,"type":33},"2026-02-19",{"date":89,"type":21},"2026-02-20",{"date":91,"type":21},"2026-03-30",{"name":93,"class":68},"Bezmialem Vakif University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":115,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":41},"100622220","comprehensive-multicenter-study-on-the-management-of-acute-pain-following-thoracic-combat-related-trauma-in-ukraine-100622220","NCT07380789","Comprehensive Multicenter Study on the Management of Acute Pain Following Thoracic Combat-Related Trauma in Ukraine","Management of Acute Pain After Thoracic Combat Trauma: A Multicenter Study in Ukraine","CMS-APT-UA","Inclusion Criteria:\n\n* Age ≥18 years\n* Thoracic trauma from combat-related injuries\n* VNRS ≥4 for acute thoracic pain\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe coagulopathy\n* Infection at intervention site\n* Allergy to local anesthetics\n* Inability to perform spirometry","60 Years",{"count":104,"type":21},50,[24],"This study is a multicenter clinical trial conducted in Vinnytsia, Rivne, and Lviv, Ukraine, focusing on the management of acute pain following thoracic injuries sustained during combat. The main purpose of the study is to evaluate and compare the effectiveness and safety of two minimally invasive procedures, cryoablation and radiofrequency ablation, in controlling severe chest pain and improving patients' recovery. Cryoablation involves applying extreme cold to specific intercostal nerves to reduce pain signals, while radiofrequency ablation uses controlled heat to achieve a similar effect. Both procedures target the nerves responsible for transmitting pain from the injured areas and are performed by experienced clinicians under careful monitoring to minimize risks. Adult patients who have experienced thoracic combat trauma and are experiencing moderate to severe pain may be eligible to participate in the study if they are able to provide informed consent and comply with the study procedures. Participants will be randomly assigned to receive either cryoablation or radiofrequency ablation. Pain intensity will be assessed before the procedure, and then again at four, twenty-four, and seventy-two hours afterward using a standardized verbal numeric rating scale. In addition to measuring changes in pain, the study will monitor opioid medication use to determine whether either procedure reduces the need for pain-relieving drugs. Mechanical pain sensitivity will be evaluated using Von Frey testing, and pulmonary function will be assessed using incentive spirometry to determine whether pain reduction improves the ability to breathe deeply and cough effectively. The impact of pain on daily activities, quality of life, and emotional well-being will also be measured using validated tools such as the LANS scale, the McGill Pain Questionnaire, and the PHQ-9 depression screening questionnaire. The study aims to provide important information on the relative benefits and risks of cryoablation and radiofrequency ablation for the treatment of acute thoracic pain, including changes in pain intensity, opioid consumption, respiratory function, and overall comfort. Potential risks associated with the procedures include temporary soreness, bruising, or rare complications, but all interventions are performed under strict safety protocols. Participation in this study may allow patients to experience better pain control, potentially reduced reliance on opioid medications, and faster recovery, while contributing valuable data that could improve pain management strategies for other patients in similar circumstances. Data collected during the study will be analyzed to compare the effectiveness of the two procedures and to identify factors that may influence outcomes, such as age, body mass index, the number of intercostal levels treated, and baseline pain scores. The study provides a structured, evidence-based approach to understanding acute pain management after thoracic combat injuries and aims to support clinicians in making informed decisions to improve patient care. For patients, families, and healthcare providers, this research offers an opportunity to participate in a carefully monitored clinical trial designed to enhance recovery and reduce suffering after serious chest trauma while advancing medical knowledge in the field of pain management.",[108,109,27,110,111,112,113,114],"Pain Management","Thoracic Trauma","Quality of Life","Functional Outcome","Depression in Adults","Neuropathic Pain","Hypoesthesia",[116,109,117,118,119],"Acute Pain Management","Cryoablation","Radiofrequency Ablation","Combat-Related Injury","2026-01-24",{"date":122,"type":33},"2026-02-02",{"date":124,"type":33},"2026-01-01",{"date":35,"type":21},{"name":127,"class":68},"Lviv National Medical University",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100608044","asthma-intervention-with-residential-ventilation-and-air-cleaner-airvac-study-100608044","NCT07196436","Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study","Energy Recovery Ventilation and Air Cleaner Interventions to Improve Indoor Air Quality, Mold Control, and Asthma-Related Health Outcomes Among Inner-City Children and Adults in Low-Income Households","Inclusion Criteria:\n\n* Individuals with physician-diagnosed asthma, including both adults and children aged 5-17\n* Homeowners living in the DFW metropolitan area, TX\n\nExclusion Criteria:\n\n* Participants living in homes with any smokers","5 Years",{"count":137,"type":21},80,[24],"The primary goal of this study is to investigate the comparative long-term (i.e., 1-year) effectiveness of energy recovery ventilators (ERVs) and portable air cleaners (PACs) in reducing indoor air pollutants and mold levels and improving asthma-related health outcomes in inner-city children and adults with asthma in low-income households in the Dallas-Fort Worth (DFW) metropolitan area, TX. Secondary goals include: (1) examining associations among asthma outcomes, exposure to indoor air pollutants and mold, and housing-related factors, (2) conducting a cost-benefit analysis of ERV and PAC interventions for improving IAQ, mold control, and health outcomes, and (3) evaluating the utility of cost-effective methods and protocols for measuring IAQ and mold for indoor air pollution epidemiology studies and for providing practical information to patients and their physicians. Using a double-blind, placebo-controlled randomized controlled trial, 80 households will be assigned to receive active or placebo versions of ERVs or PACs. Environmental exposures and housing conditions will be monitored alongside comprehensive health assessments, including lung function tests and validated surveys on asthma control, quality of life, stress, and sleep quality.",[141,27,110,142,143],"Asthma Control","Stress","Sleep Quality",[145,141,27,146,110,142,143,147,148,149,150,151],"Asthma","Lung Function","Indoor Air Quality","Residential Ventilation","Air Cleaner","Air Filtration","Mold","2025-10-27",{"date":154,"type":33},"2025-10-29",{"date":156,"type":33},"2025-10-10",{"date":158,"type":21},"2028-02-28",{"name":160,"class":68},"The University of Texas at Arlington",2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100607667","phase-2-effect-of-linvemastat-in-patients-with-partially-controlled-asthma-symmponia-100607667","NCT07191535","Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)","A Multinational Randomized Double-Blind Placebo-Controlled Phase 2 Study to Evaluate the Effect of Linvemastat (FP-020) in Patients With Partially Controlled Asthma on Inhaled Corticosteroids and Long-Acting Beta-Agonists (syMMPonia Study)","syMMPonia","Inclusion Criteria:\n\n* Patients aged 18 - 85 years at the time of signing informed consent\n* Patient is able to provide written informed consent.\n* Documented physician´s diagnosis of Type 2 high asthma, as per the Global Initiative for Asthma (GINA) 2023 guideline 2023 at Screening.\n* Patients with existing treatment with at least low to medium doses of ICS therapy in combination with LABA as a second controller for at least 90 days and a stable\u002Foptimized dose ≥30 days prior to Day 1. Patients on triple therapy with a long-acting muscarinic antagonist (LAMA) will be excluded.\n* An ACQ score ≥ 1.5 at Screening.\n* Patients with a pre-bronchodilator FEV1 value of 40% to 80% of the patient's predicted value at Screening.\n* Patients must have experienced at least once, within 2 years prior to Screening, one of the following asthma exacerbation events: Treatment with a systemic steroid (oral or parenteral) for worsening asthma. Hospitalization or emergency medical care visit for worsening asthma.\n* Males with a partner of childbearing potential must use a condom for the duration of study treatment and at least 96 hours after discontinuing the study drug.\n* Female patients of childbearing potential (including those \\\u003C 1 year post-menopausal) must use a highly effective method of contraception per Clinical Trial Facilitation Group (CTFG) recommendation during the conduct of the study and for 30 days after the last dose of study drug. Highly effective contraceptive measures for female patients of childbearing potential include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (when partner is the sole sexual partner of the female patient and when the partner has received medical assessment of the surgical success), sexual abstinence.\n* Women not of childbearing potential are defined as: Post-menopausal women (defined as at least 12 months with no menses without an alternative medical cause); in women \\\u003C45 years of age, a high follicle-stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy; OR Have had a hysterectomy and\u002For bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation\u002Focclusion at least 6 weeks prior to Screening OR Have a congenital or acquired condition that prevents childbearing.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Current smoker (including vaping) or cessation of smoking within the 6 months prior to Day 1, or \\> 10 pack-year history of smoking.\n* Participation in another clinical trial of an investigational agent within 3 months (small molecule) \u002F 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer, prior to randomization.\n* Evidence of COVID-19 infection at Screening, as judged by the Investigator.\n* Advanced congestive heart failure \\[New York Heart Association (NYHA) class 3 or 4\\].\n* Known hypersensitivity to any component of the formulation of linvemastat or any component of the excipient.\n* Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.\n* History of solid organ transplant.\n* Anti-immunoglobulin E (IgE) therapy \\[e.g., omalizumab (Xolair®)\\] within 130 days prior to Screening or any other biologic therapy \\[including anti-TSLP, anti-IL-4\u002F4R or IL-5\u002F5R monoclonal antibodies (mAb)\\] or systemic immunosuppressant (e.g., methotrexate) to treat inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 2 months or 5 half-lives prior to Screening, whichever is longer.\n* Evidence of active tuberculosis (TB) infection at Screening, as judged by the Investigator.\n* Active acute or chronic psychiatric illness that, in the opinion of the Investigator, may prevent from complying with study instructions.\n* Known positive history of malignancy within 5 years of Screening (with the exception of basal cell skin cancer, carcinoma in-situ of the cervix, or low-risk prostate cancer after curative therapy).\n* Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) infection at Screening.\n* Concurrent emphysema.\n* Use of any therapeutics that are strong inhibitors and inducers of CYP3A4 or CYP2C8 \\[e.g., rifampicin, ketoconazole, phenytoin, ritonavir, macrolide antibiotics (e.g., telithromycin), and carbamazepine\\].\n* History of liver dysfunction, including patients with moderate (Child-Pugh B) or severe (Child-Pugh C) impairment or disordered coagulation.\n* Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia \\[VT\\], multifocal or frequent premature ventricular contractions, clinically significant bundle branch block or axis deviation \\[as assessed by PI\\], or abnormal Q waves). In the case of a corrected QT interval using Fridericia's formula (QTcF) interval \\>450 ms (men) or \\>480 ms (women; patients with bundle branch block) or PR (P to QRS) interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.\n* Known uncontrolled hypertension or diabetes at the discretion of the Investigator.\n* Any condition that required hospitalization (except for asthma exacerbation) within the 3 months prior to Day 1 or is likely to require so during the study.\n* Clinically significant abnormalities in the Screening physical examination, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent asthma in the opinion of the Investigator and Medical Monitor should preclude the patient's participation in the clinical study.\n* The following laboratory parameters are excluded:\n\n  1. Hemoglobin (Hg) \\\u003C10 g\u002FdL (100 g\u002FL)\n  2. White blood cells (WBC) \\\u003C 3000\u002FμL (\\\u003C 3000\u002Fmm3). African American patients who are known to have low WBC of \\\u003C 3000\u002FμL but ≥ 1500\u002FμL will be eligible.\n  3. Platelet count \\\u003C 70,000\u002FμL (70,000\u002Fmm3)\n  4. Serum creatinine \\> 1.5 x upper limit of normal (ULN)\n  5. Glomerular filtration rate ≤ 60 mL\u002Fmin\u002F1.73 m2 or evidence of acute kidney injury or history of severe hypersensitivity reactions to gadolinium-based contrast agents\n  6. Serum total bilirubin \\> 1.5 ULN\n  7. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 x ULN or serum alkaline phosphatase \\> 2 x ULN","85 Years",{"count":172,"type":21},135,[174],"PHASE2","This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, participants receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 16 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.",[177,27,178],"Asthma (Diagnosis)","Moderate-to-Severe Asthma",[180,181,182],"central spirometry","type-2 (T2) high asthma","asthma management","2025-10-15",{"date":185,"type":33},"2025-10-20",{"date":124,"type":21},{"date":188,"type":21},"2027-09-01",{"name":190,"class":191},"Foresee Pharmaceuticals Co., Ltd.","INDUSTRY",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":41},"100601608","effect-of-incentive-respiratory-training-on-pulmonary-functions-and-functional-capacity-in-children-with-b-thalassemia-major-100601608","NCT07112703","Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major","Inclusion Criteria:\n\n1. Diagnosed as thalassemia \\& subjected to blood transfusion\n2. Their age range from 6 to 10 years old\n3. Both sexes, male and female, will participate.\n4. Subjects are able to follow simple verbal commands or instructions included in the procedures.\n\nExclusion Criteria:\n\n1. Children with mental retardation or any other disability .\n2. Children with visual or hearing defects.\n3. Children with cardiovascular, chest pulmonary, and heart diseases.\n4. Children with any postoperative cardiovascular, chest pulmonary, and heart conditions.","6 Years","10 Years",{"count":104,"type":21},[24],"The study was done to:\n\n1. Investigate the effect of respiratory training on functional lung capacity and\n2. To detect the effect of respiratory training on pulmonary functions in children with β-thalassemia major.\n3. To detect the level of oxygen saturation and heart rate during and after blood transfusion in children with β-thalassemia major.",[204,27,205,206,207],"Incentive Spirometer","Functional Capacity","Child, Only","Thalassemia Major","2025-08-02",{"date":210,"type":33},"2025-08-08",{"date":212,"type":33},"2025-04-07",{"date":214,"type":21},"2025-10-08",{"name":216,"class":68},"Rawan Mohammed Khairy Mostafa Elsawy",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":76,"enrollmentInfo":225,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":161},"100524278","vitamin-c-to-decrease-effects-of-smoking-in-pregnancy-on-infant-lung-function-vcsip-longer-term-follow-up-100524278","NCT06106646","Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up","Assessing the Effect of Vitamin C on Infant Lung Function When Given to Pregnant Women Who Smoke - (Long Term Follow-up of a Randomized Trial)","VCSIP","Inclusion Criteria:\n\n* Women and their offspring randomized to vitamin C versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original VCSIP study\n\nExclusion Criteria:\n\n* participants who specifically withdraw consent",{"count":226,"type":21},225,"The overall aims of this protocol are to determine whether prenatal supplementation with vitamin C to pregnant smokers can improve pulmonary function at 10 years of age in their offspring. This is an additional continuation of the Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) trial, to follow the offspring through 10 years of age. The hypothesis for this protocol is an extension of the VCSIP trial that supplemental vitamin C in pregnant smokers can significantly improve their children's airway function tests. The investigators aim to demonstrate sustained improvement in airway\u002Fpulmonary function and trajectory through 10 years of age.",[145,27,229,230],"Wheezing","In Utero Nicotine",[145,27,232,233,234,235,236,237,146,238,239],"Pulmonary Function Testing","Wheeze","Vitamin C","Antioxidants","Forced Expiratory Flows","Spirometry","Epigenetics","High resolution CT scans","2025-03-17",{"date":242,"type":33},"2025-03-18",{"date":244,"type":33},"2023-10-11",{"date":246,"type":21},"2028-08",{"name":248,"class":68},"Oregon Health and Science University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":256,"maxAge":102,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":270,"leadSponsor":272,"locationsCount":41},"100567101","additional-effects-of-ujjayi-pranayama-100567101","NCT06663800","Additional Effects of Ujjayi Pranayama","Additional Effects of Ujjayi Pranayama on Pulmonary Function in Post Coronary Artery Bypass Graft","Inclusion Criteria:\n\n* Participants who have 1st post op Day\n* Hemodynamically stable \\& well oriented patient\n* Extubated Patient\n* Voluntary based patients\n* After approval of surgeon CABG patient were recruited\n* Tachypnea\n\nExclusion Criteria:\n\n* Hemodynamically unstable,\n* Uncontrolled Hypertension,\n* MSK disease,\n* Any previous history of tuberculosis,\n* Neurological disease ,\n* Acute exacerbation of COAD \\& Asthma Attack,\n* Any trauma, anxiety or Rib fracture case ,\n* During surgery complaint of graft failure ,\n* Unwilling to participate ,\n* Postural Hypotension.","35 Years",{"count":258,"type":21},36,[24],"Studying the impact of Ujjayi pranayama on post-Coronary Artery Bypass Grafting (CABG) patients has the potential to positively influence healthcare. This research fosters a patient-centered approach, enhancing cardio respiratory function. Patient education on these practices can empower individuals, actively contributing to their recovery and overall well-being.",[27,262],"Coronary Artery Disease",[264,265,27],"Ujjayi Paranyama","Coronary artery bypass grafting","2024-10-28",{"date":268,"type":33},"2024-10-29",{"date":266,"type":21},{"date":271,"type":21},"2025-01-18",{"name":273,"class":68},"Riphah International University",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":41},"100552774","deep-learning-for-preoperative-pulmonary-assessment-in-thoracic-ct-100552774","NCT06477458","Deep Learning for Preoperative Pulmonary Assessment in Thoracic CT","Application of Deep Learning in CT Imaging of Elective Thoracic Surgery Patients: Assessing Preoperative Abnormal Pulmonary Function","Inclusion Criteria:\n\n* (1) Signing of the informed consent form;\n* (2) Male or female, aged 18-75 years;\n* (3) Undergoing elective thoracic surgery;\n* (4) Good preoperative pulmonary function cooperation and complete reporting;\n* (5) Preoperative chest single\u002Fdual phase CT scans without significant artefacts and with complete imaging;\n* (6) The interval between preoperative pulmonary function and single\u002Fdual phase CT scans does not exceed one month.\n\nExclusion Criteria:\n\n* (1) Poor preoperative pulmonary function cooperation or missing reports;\n* (2) Preoperative chest single\u002Fdual phase CT scans exhibit significant artefacts or image omission;\n* (3) The interval between preoperative pulmonary function and single\u002Fdual phase CT scans exceeds one month;\n* (4) Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);\n* (5) Coexisting with other severe functional impairments;\n* (6) Patients with obstructive lesions such as airway or esophageal stenosis;\n* (7) Height beyond the predicted equation range (Female \\\u003C 1.45m; Male \\\u003C 1.55m);\n* (8) Medication use before pulmonary function testing that does not meet the cessation guidelines;\n* (9) Pulmonary function report quality graded D-F.","75 Years",{"count":283,"type":21},2000,"The trial was designed as a single-centre, non-interventional prospective observational study to utilize deep learning technology combined with computed tomography (CT) images to precisely predict the pulmonary function indicators of thoracic surgery preoperative patients.",[286,27,287],"Elective Thoracic Surgery","Deep Learning","2024-06-26",{"date":290,"type":33},"2024-06-27",{"date":292,"type":33},"2023-10-01",{"date":294,"type":21},"2024-12-30",{"name":296,"class":68},"The First Affiliated Hospital of Guangzhou Medical University",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":304,"targetDuration":199,"studyType":79,"phases":4,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":41},"100461483","a-national-registry-on-chinese-patients-with-cystic-fibrosis-100461483","NCT05289245","A National Registry on Chinese Patients With Cystic Fibrosis","A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Cystic Fibrosis (CF-CHINA)","Inclusion Criteria:\n\nFulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.\n\nExclusion Criteria:\n\nPatients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease",{"count":305,"type":21},200,"Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.",[27],"2022-03-13",{"date":310,"type":33},"2022-03-21",{"date":312,"type":21},"2022-04-01",{"date":314,"type":21},"2032-10-01",{"name":316,"class":68},"Peking Union Medical College Hospital",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":324,"minAge":4,"maxAge":4,"enrollmentInfo":325,"targetDuration":199,"studyType":79,"phases":4,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":41},"100300655","a-national-registry-on-chinese-patients-with-lymphangioleiomyomatosis-100300655","NCT03193892","A National Registry on Chinese Patients With Lymphangioleiomyomatosis","A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA)","Inclusion Criteria:\n\n1. Gender: female.\n2. Age: no limitation.\n3. Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS\u002FJRS and ERS criteria. (2) Investigators recommend including of the patient.\n\nExclusion Criteria:\n\n1. Suspected LAM patients without other supporting evidence for LAM diagnosis.\n2. No diffuse cystic lesions in the lung.\n3. Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established.\n4. Without signed informed consent.\n5. Difficult to follow up.","FEMALE",{"count":326,"type":21},1500,"Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.",[27],[330,331,332],"registry","China","lymphangioleiomyomatosis","2021-09-18",{"date":335,"type":33},"2021-09-24",{"date":337,"type":33},"2017-01-01",{"date":339,"type":21},"2026-10-01",{"name":316,"class":68}]